Recently developed XPO1 inhibitors showed success in slowing tumorigenesis in a variety of cancers and the selective inhibitor of nuclear export (SINE), Selinexor (KPT-330, Karyopharm Therapeutics), was approved for relapsed multiple myelomas in 2020 (Chen et al. 2018). This evidence concerns the gene XPO1 and cancer.